'Myriad' Patent Issues at Stake as High Court Conferences

At Friday's conference session, the Supreme Court will consider for the second time whether to grant cert to Association for Molecular Pathology v. Myriad Genetics Inc., a challenge to the Salt Lake City-based company's claims on the BRCA1 and BRCA2 genes used in diagnostics for breast and ovarian cancers. The court's decision on whether to hear the case is expected Monday.